哈莫尼生物科技 HRMY
$33.11 +$0.64 (+1.97%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $33.00 -0.33%
开盘$32.70
昨收$32.47
当日区间$32.27 – $33.38
成交量787.2K
市值$1.94B
市盈率（TTM）11.0
股息率–
HRMY 相关新闻
匹配 Harmony Biosciences 或代码 HRMY 的头条新闻，按最新排序。
- Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $51
- Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50
- A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $30 to $55
- Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $39 正面
- Wolfe Research Initiates Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $60
- H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $55
- Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $51 正面
- Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50
- Goldman Sachs Upgrades Harmony Biosciences(HRMY.US) to Hold Rating, Raises Target Price to $37 正面
- Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $45
- Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)
- Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $36 正面
- Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $45 正面
- Piper Sandler Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Cuts Target Price to $46 负面
- Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $72 正面
暂无评论——快来第一个聊聊 HRMY。